Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Roche Notches Big IO Win With Tecentriq/Avastin Combo In First-Line HCC

Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.

Clinical Trials ImmunoOncology

How Proximity Creates Partnerships

Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

Business Strategies Deals

Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy

The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.

Deals Research and Development Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register